Hamlet Pharma has been granted permission for a 2-year follow up study
The phase I/II study in patients with bladder cancer addresses the safety of our drug candidate Alpha1H and measures biomarkers of efficacy. The protocol is designed for rapid evaluation, as the patients are under treatment for only one month each. So far, even though the study protocol is blinded and placebo-controlled, we can conclude that the safety profile is excellent.The short-term effects of Alpha1H in this patient group will be evaluated, as soon as all patients have completed the one-month study. In addition, we intend to follow the patients for a longer period of time, to